British magazine Emerging Microbes&Infections has published CoviVac vaccine study

The British scientific journal Emerging Microbes&Infections has published a study of the Russian vaccine CoviVac on animals, BBC News reports. The vaccine has gained the greatest popularity at home as the "mildest" vaccine, with a minimum of side effects. Moreover, it is the most scarce due to the peculiarities of production. The vaccine has been used since spring. In June, the third phase of testing began - on volunteers (it will last six months).

The study was carried out on mice, rats, hamsters, marmosets. All the subjects perfectly tolerated even multiple administrations of the drug, from which it follows that CoviVac is not toxic.

The effect of the vaccine on the reproductive properties of organisms was tested separately, and it was not found.

The level of neutralizing antibodies (it is believed that they are needed to counteract covid) in the test subjects was very high - in 100% of the vaccinated test subjects two weeks after the second dose, and it persisted for a year.

The drug's efficacy on the human body is being studied now, during the third phase of testing.

CoviVac is an inactivated vaccine (produced according to the well-studied technology of the killed vaccine). BBC experts say that an inactivated vaccine may indeed cause fewer side effects than mRNA vaccines (Pfizer, Moderna) or drugs on adenoviral vectors (Sputnik, AstraZeneca, Johnson & Johnson).

After vaccination with mRNA and adenovirus vaccines, antibodies are produced only to the S-protein of the virus. After the inactivated vaccine, antibodies should be produced for all parts of the virus.

However, in the "people reports" group, many participants reported that they did not develop antibodies to the S-protein after CoviVac. Some report the presence of antibodies to the S-protein, but their titers were much lower than the average after Sputnik. This can lead to the fact that the vaccinated person will be still at risk of getting infected.